Literature DB >> 12413503

Serum to urinary sodium concentration ratio is an estimate of plasma renin activity in congestive heart failure.

GianCarlo Marenzi1, Gianfranco Lauri, Emilio Assanelli, Marco Grazi, Jeness Campodonico, Gabriella Famoso, Piergiuseppe Agostoni.   

Abstract

We investigated the relationship between plasma renin activity (PRA) and serum ([sNa(+)]) and urinary ([uNa(+)]) sodium concentrations in 124 congestive heart failure (CHF) patients (II-IV NYHA class) and 20 healthy subjects. According to PRA (> or <3 ng ml(-1) h(-1)) and [sNa(+)] (> or <135 mEq l(-1)), patients were classified as Group A (normal PRA and normal [sNa(+)], n=39), Group B (increased PRA and normal [sNa(+)], n=62) and Group C (low [sNa(+)], n=23). Measurements were performed at rest and, in 26 cases, after extracorporeal ultrafiltration (UF). At rest, [sNa(+)] and [uNa(+)], and their difference ([sNa(+)]-[uNa(+)]), were linearly correlated with PRA, but the values did not allow differentiation of control subjects from patients or differentiation of patients with from those without renin-angiotensin system (RAS) activation. Conversely, the [sNa(+)]/[uNa(+)] ratio showed the best correlation with PRA (r=0.79, P<0.0001). UF-induced PRA changes were linearly correlated with [sNa(+)]/[uNa(+)] ratio changes (r=0.67, P=0.002), but not with those of [sNa(+)], [uNa(+)] and [sNa(+)]-[uNa(+)]. In CHF, the [sNa(+)]/[uNa(+)] ratio best correlates with PRA and reflects the basal activity as well as the rapid changes (as those induced by UF) of the RAS. Therefore, it can be considered a strong and easily available marker of PRA. Copyright 2002 European Society of Cardiology

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12413503     DOI: 10.1016/s1388-9842(02)00097-1

Source DB:  PubMed          Journal:  Eur J Heart Fail        ISSN: 1388-9842            Impact factor:   15.534


  5 in total

1.  Natriuretic Response Is Highly Variable and Associated With 6-Month Survival: Insights From the ROSE-AHF Trial.

Authors:  Daniel Z Hodson; Matthew Griffin; Devin Mahoney; Parinita Raghavendra; Tariq Ahmad; Jeffrey Turner; F Perry Wilson; W H Wilson Tang; Veena S Rao; Sean P Collins; Wilfried Mullens; Jeffrey M Testani
Journal:  JACC Heart Fail       Date:  2019-05       Impact factor: 12.035

2.  Diagnostic value of plasma and urinary 2-hydroxyglutarate to identify patients with isocitrate dehydrogenase-mutated glioma.

Authors:  Giuseppe Lombardi; Giuseppe Corona; Luisa Bellu; Alessandro Della Puppa; Ardi Pambuku; Pasquale Fiduccia; Roberta Bertorelle; Marina Paola Gardiman; Domenico D'Avella; Giuseppe Toffoli; Vittorina Zagonel
Journal:  Oncologist       Date:  2015-04-10

Review 3.  Vasopressin receptor antagonists in patients with chronic heart failure.

Authors:  R De Vecchis; C Cantatrione; D Mazzei
Journal:  Herz       Date:  2016-09-15       Impact factor: 1.443

4.  Effects of empagliflozin on cardiorespiratory fitness and significant interaction of loop diuretics.

Authors:  Salvatore Carbone; Justin M Canada; Hayley E Billingsley; Dinesh Kadariya; Dave L Dixon; Cory R Trankle; Leo F Buckley; Roshanak Markley; Chau Vo; Horacio Medina de Chazal; Sanah Christopher; Raffaella Buzzetti; Benjamin W Van Tassell; Antonio Abbate
Journal:  Diabetes Obes Metab       Date:  2018-04-23       Impact factor: 6.577

Review 5.  Vasopressin Receptor Antagonists for the Correction of Hyponatremia in Chronic Heart Failure: An Underutilized Therapeutic Option in Current Clinical Practice?

Authors:  Renato De Vecchis; Claudio Cantatrione; Damiana Mazzei; Cesare Baldi
Journal:  J Clin Med       Date:  2016-10-02       Impact factor: 4.241

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.